title: [New approach to the treatment of arteritis using a combination of drugs and hypervolemia with clinical and biological monitoring].
abstract: The clinical survey is based on the history, the physical examination, analysis of the laboratory tests, a cardiological and ophthmological examination and Doppler studies. This examination allows classification of the stage of the arteritis. We have developed a treatment consisting of continuous infusions of isotonic glucose-saline combined with Eucilat, a vaso-dilator. We increase the quantity of fluid and vasodilator to as much as 4 litres per 24 hours for 18 vials of Eucilat. The blood pressure and the urinary output are regularly monitored. A full survey is performed on the 5th day. The course of treatment should not exceed 20 days. From the beginning of treatment, we combine a modifier of the red cell wall, Torental 400 and an oxygenator, Duxil. After the infusions, the treatment is continued as an out-patient with a combination of Duxil-Torental 400-Eucilat.
mesh_terms: D000368:Aged; D015765:Almitrine; D001167:Arteritis / Q000628:therapy*; D001572:Benzofurans / Q000008:administration & dosage*; D001794:Blood Pressure; D004231:Diuresis; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005947:Glucose / Q000008:administration & dosage*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D013805:Theobromine / Q000031:analogs & derivatives*; D014665:Vasodilator Agents / Q000008:administration & dosage*; D015016:Yohimbine / Q000008:administration & dosage*
chemical_list: D001572:Benzofurans; D004338:Drug Combinations; D010879:Piperazines; D014665:Vasodilator Agents; D015016:Yohimbine; C000124:benfurodil; C037558:almitrine, raubasine drug combination; D015765:Almitrine; D005947:Glucose; D013805:Theobromine; D010431:Pentoxifylline
vernacular_title: Nouvelle approche du traitement des artérites par association médicamenteuse et hypervolémie sous controle clinique et biologique.